Hospital de la Princesa is organizing a conference on the latest developments in the field of prostate cancer.

Prostate cancer is the second most common cancer diagnosed in men worldwide, with approximately 1.5 million new cases diagnosed each year. In Spain, it was the most common cancer in men in 2023 and 2022, with almost 29,000 new cases reported. Aging is a major risk factor for this type of cancer, with a prevalence of around 60% in people over 80 years of age.

These figures show the need for such conferences, which share knowledge based on the latest scientific evidence through the participation of national and international experts in the field of uro-oncology. Notable among these experts were Almudena Zapatero, a radiation oncologist from the center itself and a panelist at the American Congress of Radiation Oncology, Elena Castro, a medical oncologist from the 12 October Hospital, and Dr. Emilio Rios, a urologist from the La Paz Hospital. other.

The meeting, held on April 18, provided an excursion into the various stages of diagnosis and treatment of prostate cancer, the biological basis of this type of tumor, decision-making in patients with metastatic prostate cancer from a multidisciplinary approach, new therapeutic approaches, combined systemic treatment (treatment that affects cells along the whole body) with local treatment, as well as future therapeutic goals. There was also a presentation of a real clinical case.

The conference was opened by the medical director of La Princesa Hospital, Gloria Torralbo Caballero, accompanied by Luis. San José Manzo, head of the urological service at the University Hospital of La Princesa, and Nuria Romero Laorden, specialist in the medical oncology service of the center.

More than 1000 interventions per year

The Urology Service at La Princesa University Hospital carries out more than 1,000 interventions annually, including elective outpatient and emergency procedures, and approximately 14,000 outpatient consultations; All this is combined with teaching and cutting-edge research carried out in collaboration with other services such as medical oncology and radiotherapy.